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Introduction
Juvenile idiopathic arthritis (JIA) is the most common
rheumatic disease among children. Among patients with
JIA often meets resistance to the therapy of various drugs,
including nonsteroidal anti-inflammatory drugs (NSAIDs),
intraarticular injections and physiotherapy. For the treat-
ment of JIA is used several groups of drugs: NSAIDs, cor-
ticosteroids (CS), immunosuppressive drugs and
biologically active substances obtained genno-ingenerian.
Application NSAIDs and GS have anaesthetic and
anti-inflammatory effects, but do not contribute to the
prevention of destruction of the joints and disability of
patients. The ≪gold standard≫ in the treatment of JIA
can be considered methotrexate (MTX) - cytostatic drug
groups of antimetabolites, antagonists folic acid. MTX
has expressed immunosupression action, even at rela-
tively low doses, with no noticeable hematologic toxicity.
Despite this, when taking methotrexate recommended
clinical and laboratory monitoring is needed to prevent
side effects. According to various authors, about 70% of
patients receiving MTX consists in the remission of the
disease.
Objectives
The aim of our study is to define the efficient MTX
concentration in the blood serum of patients with JIA.
Methods
All children included in the study received basic therapy
with methotrexate dose of 15 mg/m2 over 3 months
and more. All the children were conducted routine
methods of research, objective examination and deter-
mined the MTX concentration in the serum.
Results
We examined 103 child patients with JIA, among which
- 65 (63,11%) girls and 38 (36,89%) boys with various
forms of juvenile idiopathic arthritis. Children with
polyarthritis - 46 (44,66%), with olygoarthritis JIA - 25
children (24,27%), systemic type of arthritis diagnosed
with 14 children (13,59%), enthesitassociated arthritis
met in 18 patients (17,48%).
35 patients (34%) to the treatment with MTX added
biologically active therapy, 11 patients (10,68%) receive
in addition to the MTX therapy sulfasalazine, 24 child
(23,3%) - cyclosporine A, 37 children (35,92%) being
prednisone or methylprednisone (in tablets or in the
form of a pulse therapy). Noteworthy is that 46 (44,66%)
patients have the positive effects of MTX monotherapy,
does not require the appointment of additional drugs.
Conclusion
According to the information we received data MTX
concentration in the serum was in the range of 0.76
mmol/lIA to 3,96 mmol/L. Significant differences
depending on the activity of the disease, type of arthritis,
treatment duration MTX were received. Thus the defini-
tion of MTX concentration in the blood serum of
patients with JIA not let to forecast the efficiency of the
therapy.
MTX has a good safety profile. To reduce the risk of
side effects, appoint folic acid at a dose of 1-5 mg) in
the days when MTX is not used, because while receiving
folic acid may reduce the effectiveness of MTX. An
important feature of the use of this drug is to use 1
time a week.
The use of cytostatic therapy (MTX) is the drug of
choice in all countries for the treatment of various
forms of JIA and is the gold standard.
SPbGPMU, St. Petersburg, Russian Federation
Rokhlina and Novik Pediatric Rheumatology 2013, 11(Suppl 2):P63
http://www.ped-rheum.com/content/11/S2/P63
© 2013 Rokhlina and Novik; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Disclosure of interest
None declared.
Published: 5 December 2013
doi:10.1186/1546-0096-11-S2-P63
Cite this article as: Rokhlina and Novik: PReS-FINAL-2050: Determination
of the concentration of methotrexate in the blood serum of patients
with JIA. Pediatric Rheumatology 2013 11(Suppl 2):P63.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rokhlina and Novik Pediatric Rheumatology 2013, 11(Suppl 2):P63
http://www.ped-rheum.com/content/11/S2/P63
Page 2 of 2
